Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tryp Therapeutics Inc
(OP:
TRYPF
)
N/A
UNCHANGED
Last Price
Updated: 3:17 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tryp Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Is Psilocybin Therapy A Potential Treatment For Fibromyalgia & Binge Eating Disorder?
September 26, 2022
Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applications - one for psilocybin therapy for fibromyalgia and another expanding...
Via
Benzinga
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio
September 26, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Veteran Finance Exec as CFO
September 19, 2022
Via
Investor Brand Network
Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma
September 14, 2022
Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options
Via
Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with IMS Investor Relations for Consulting, Communications and Outreach Services
September 13, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Expands IP Portfolio with New Provisional Patent Application
June 29, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Health Care and Biotech Expert as New Chief Operating Officer
June 23, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
June 15, 2022
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.
Via
Benzinga
Clinical Trials Of Psilocybin Treatment For Overeating Disorder Are Ready, Here's What Results Show So Far
June 09, 2022
Tryp Therapeutics Inc. (OTCQB: TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ill-treated diseases.
Via
Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Results from Phase II Binge Eating Disorder Clinical Trial
June 09, 2022
Via
Investor Brand Network
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
June 02, 2022
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its...
Via
Benzinga
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Names New Independent Director to Board
May 25, 2022
Via
Investor Brand Network
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
May 02, 2022
The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions.
Via
Benzinga
Could Magic Mushrooms Be A Solution For Overeating? New Clinical Trial Intends To Find Out
April 28, 2022
Psilocybin, the active ingredient in “magic mushrooms,” could be part of the solution for people struggling with binge eating disorder, a condition characterized by recurring episodes of eating large...
Via
Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Doses First Patient in Clinical Trial for Psilocybin-Assisted Therapy Targeting BED
April 28, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Initiates Enrollment for Study to Evaluate TRP-8802 to Treat Binge Eating Disorder
March 23, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces New Board Appointment, Closing of First Tranche of Private Placement
February 22, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Upsizing of Private Placement
February 18, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Q1 2022 Financial Numbers
January 31, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces January 2022 Health Care Conference Schedule
January 05, 2022
Via
Investor Brand Network
FDA Approves Psilocybin For Binge Eating Study By Tryp Therapeutics
December 23, 2021
Tryp Therapeutics (CSE:TRYP) (OTCQB:
Via
Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Advancement of Binge-Eating Clinical Trial
December 23, 2021
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases FY 2021 Updates, Results
December 22, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation
December 09, 2021
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Clinical Trials, Focus Puts It ‘In Pretty Rarefied Air’
December 08, 2021
Via
Investor Brand Network
Exposures
Product Safety
FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process
December 06, 2021
Via
Investor Brand Network
Topics
Law Enforcement
Exposures
Legal
Product Safety
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference
December 03, 2021
Via
Investor Brand Network
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia
December 02, 2021
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’
December 01, 2021
Via
Investor Brand Network
Exposures
Product Safety
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays
November 29, 2021
Via
Investor Brand Network
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.